ABUS - Arbutus Biopharma Corp - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

ABUS is currently covered by 1 analysts with an average price target of $5. This is a potential upside of $0.98 (24.38%) from yesterday's end of day stock price of $4.02.

Arbutus Biopharma Corp's activity chart (see below) currently has 109 price targets and 86 ratings on display. The stock rating distribution of ABUS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 56.91% of the time, taking 312.67 days on average.

Highest price target for ABUS is $5, Lowest price target is $5, average price target is $5.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 04-Mar-2026. First documented stock forecast 03-Jul-2014.

Currently out of the existing stock ratings of ABUS, 1 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 15-Sep-2020

$5

$0.98 (24.38%)

$5

8 months 18 days ago
(04-Mar-2026)

10/15 (66.67%)

$0.25 (5.26%)

442

Buy Since 05-Nov-2021

$5

$5

1 years 7 months 22 days ago
(31-Mar-2025)

4/9 (44.44%)

$1.51 (43.27%)

420

Buy Since 17-Dec-2020

$5

$5

1 years 10 months 1 days ago
(21-Jan-2025)

5/20 (25%)

$1.79 (55.76%)

671

Hold Since 29-Dec-2021

$5

$4

4 years 9 months 20 days ago
(02-Feb-2022)

2/2 (100%)

$2.11 (73.01%)

1298

Buy Since 05-Mar-2020

$7

$7

5 years 4 months 25 days ago
(28-Jun-2021)

0/6 (0%)

$3.63 (107.72%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ABUS (Arbutus Biopharma Corp) average time for price targets to be met?

On average it took 313 days for the stock forecasts to be reached, with an average price target met ratio of 56.91%.

Which analyst most recently updated their price target on ABUS (Arbutus Biopharma Corp)?

Keay Nakae

Which analyst has the most public recommendations on ABUS (Arbutus Biopharma Corp)?

Keay Nakae works at CHARDAN CAPITAL and has 5 price targets and 3 ratings on ABUS

Which analyst is the currently most bullish on ABUS (Arbutus Biopharma Corp)?

Michael Yee with the highest potential upside of $15.98

Which analyst is the currently most reserved on ABUS (Arbutus Biopharma Corp)?

Madhu Kumar with the lowest potential downside of -$0.02
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?